Core Insights - The ALS (Amyotrophic Lateral Sclerosis) drug development landscape in China is evolving, with significant advancements in research and clinical trials, particularly in the context of funding challenges faced by startups in this field [1][6][8] Group 1: Drug Development Progress - The approval of Tofersen, the first "cause-targeted" ALS drug, in China marks a significant milestone, filling a gap for SOD1-ALS patients and aligning domestic treatment options with international standards [2][3] - Multiple ASO therapies, including Ulefnersen and siRNA therapies like RAG-17 and RAG-21, are in early clinical stages, showcasing the potential of nucleic acid-based treatments for ALS [3][4] - Domestic companies are increasingly becoming the main drivers of innovation in ALS drug development, with 15 drug development projects reported since 2025, excluding IIT research [4] Group 2: Funding Challenges - The ALS drug development sector is primarily composed of startups, which face significant funding challenges due to the limited commercial value of rare diseases and the high risk of early-stage research failures [5][6] - Despite the overall interest in innovative drugs, the financing environment for ALS remains cold, with only a few companies achieving significant funding rounds [7][8] - Companies like Shenzhi Changhua and Zhongmei Ruikang, which have advanced drugs to clinical stages, still encounter financial pressures, highlighting the common funding challenges in rare disease drug development [7][8] Group 3: Research and Regulatory Recommendations - The complexity of ALS, including unclear etiology and heterogeneous patient populations, complicates drug development, necessitating a robust support system for rare disease research [9][10] - Recommendations for improving the regulatory landscape include enhancing orphan drug recognition processes, flexible clinical trial designs, and extending market exclusivity periods to ensure adequate returns on investment [10] - Collaborative efforts are suggested to establish national rare disease patient registries and biobanks, as well as integrating international resources to create a unified disease database for ALS research [10]

Core Insights - The ALS (Amyotrophic Lateral Sclerosis) drug development landscape in China is evolving, with significant advancements in research and clinical trials, but challenges remain in funding and commercialization [1][2][9] Group 1: Drug Development Progress - The first "cause-targeted" ALS drug, Tofersen, has been approved in China, filling a gap for SOD1-ALS patients and aligning domestic treatment options with international standards [2][3] - Multiple ASO (Antisense Oligonucleotide) therapies are in early clinical stages, including Ionis Pharmaceuticals' Ulefnersen, and domestic companies like Zhongmei Ruikang are developing siRNA therapies [3][4] - Since 2025, there have been numerous drug development advancements in the ALS field in China, with at least 15 new drug candidates reported [6][7] Group 2: Funding Challenges - The ALS drug development sector is primarily driven by small and medium-sized enterprises, facing significant funding challenges due to the high costs and risks associated with early-stage research [9][10] - Initial funding for ALS projects is often reliant on external investments, as many startups lack mature products to generate revenue [10][11] - Despite the overall interest in innovative drugs, the ALS sector has seen limited large-scale financing, with only a few companies achieving significant funding rounds [10][12] Group 3: Research and Regulatory Environment - The complexity of ALS, including unclear etiology and heterogeneous patient populations, complicates drug development and increases the risk of early-stage failures [11][12] - Companies are advocating for improved regulatory frameworks to expedite drug approvals and support for rare disease research, including tax incentives and the establishment of specialized funds [12][13] - Collaborative efforts are suggested to create national registries and databases to enhance research and data sharing among stakeholders [12][13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696) 自願公告 小分子創新藥HLX99 的臨床試驗申請獲美國食品藥品管理局(FDA)批准 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，本公司自主研發的小分子創新 藥HLX99（「HLX99」）的臨床試驗申請獲美國食品藥品管理局(FDA)批准。 HLX99擬用於治療肌萎縮側索硬化(ALS）。 B. 關於HLX99 HLX99是本公司自主研發的創新型小分子偶聯化學藥物，擬用於治療肌萎縮 側索硬化(ALS)。肌萎縮側索硬化(ALS)，又稱「漸凍症」，是一種神經系統退 行性疾病，影響大腦運動皮層、腦干和脊髓的運動神經元細胞群，導致肌肉 ...